Thus, we sought to evaluate therapeutic opportunities for our PRMT5 inhibitors (C220 and PRT543) in ovarian and breast cancers, where PARP inhibitors are clinically approved in patients with HRD tumors (24, 25). Here, PRMT5 is linked to breast cancer.